<![CDATA[Bavarian Nordic — Marts 2020]]>God morgen. -:)

]]>https://dev.proinvestor.com/forum/topic/451969/bavarian-nordic-marts-2020RSS for NodeTue, 09 Jun 2026 17:24:40 GMTMon, 02 Mar 2020 05:23:18 GMT60<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 17:32:50 GMT]]>Bavarian: https://www.proinvestor.com/investornyt/658201/bavarian-nordic-offentliggor-storaktionaermeddelelse-fra-nordea-bank-abp

]]>https://dev.proinvestor.com/forum/post/10492619https://dev.proinvestor.com/forum/post/10492619Tue, 31 Mar 2020 17:32:50 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 13:48:12 GMT]]>Luk 233,60 oppe med +12,09% - endnu god dag på kontoret!

]]>https://dev.proinvestor.com/forum/post/10492618https://dev.proinvestor.com/forum/post/10492618Tue, 31 Mar 2020 13:48:12 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 12:49:50 GMT]]>PDUFA Date:
https://www.fool.com/knowledge-center/what-is-a-pdufa-date.aspx
PDUFA drug approval dates:
https://www.fdatracker.com/fda-calendar/

]]>https://dev.proinvestor.com/forum/post/10492614https://dev.proinvestor.com/forum/post/10492614Tue, 31 Mar 2020 12:49:50 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 12:23:28 GMT]]>takker exitnu

]]>https://dev.proinvestor.com/forum/post/10492615https://dev.proinvestor.com/forum/post/10492615Tue, 31 Mar 2020 12:23:28 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 12:23:04 GMT]]>udover de 60 dage, som de til at godkende ansøgnin
gen

]]>https://dev.proinvestor.com/forum/post/10492612https://dev.proinvestor.com/forum/post/10492612Tue, 31 Mar 2020 12:23:04 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 12:22:40 GMT]]>6-12 måneder 🙂

]]>https://dev.proinvestor.com/forum/post/10492617https://dev.proinvestor.com/forum/post/10492617Tue, 31 Mar 2020 12:22:40 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 12:17:42 GMT]]>Har vi en tidshorisont på ansøgningen, hvornår FDA skal melde noget tilbage

]]>https://dev.proinvestor.com/forum/post/10492609https://dev.proinvestor.com/forum/post/10492609Tue, 31 Mar 2020 12:17:42 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:55:39 GMT]]>Selskabet afsluttede fase 3-forsøg i november og oplyste der at selskabet i begyndelsen af 2020 vil indsende New Drug Application-ansøgning til FDA.

/ritzau/FINANS

]]>https://dev.proinvestor.com/forum/post/10492613https://dev.proinvestor.com/forum/post/10492613Tue, 31 Mar 2020 11:55:39 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:55:33 GMT]]>Hypopal anvendes til nødbehandling af diabetikere i forbindelse med for lavt blodsukkerniveauer.

Pennen er baseret på lægemiddelkandidaten Dasiglucagon, der skal bruges til behandling af episoder med for lavt blodsukker hos diabetikere - såkaldt hypoglykæmi.

]]>https://dev.proinvestor.com/forum/post/10492610https://dev.proinvestor.com/forum/post/10492610Tue, 31 Mar 2020 11:55:33 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:55:22 GMT]]>Zealand Pharma ansøger FDA om brug af nødpen

Zealand Pharma har - som planlagt - indsendt en New Drug Application-ansøgning til de amerikanske sundhedsmyndigheder, FDA, om brug af selskabets nødpen, Hypopal.

Det oplyser selskabet tirsdag.

]]>https://dev.proinvestor.com/forum/post/10492607https://dev.proinvestor.com/forum/post/10492607Tue, 31 Mar 2020 11:55:22 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:46:24 GMT]]>The submission encompasses three Phase 3 trials which met all primary and key secondary endpoints with a median time to recovery from hypoglycemia of only 10 minutes

Zealand Pharma remains on-track to build commercial infrastructure in the U.S. for the anticipated Dasiglucagon HypoPal Rescue Pen launch in 2021

]]>https://dev.proinvestor.com/forum/post/10492606https://dev.proinvestor.com/forum/post/10492606Tue, 31 Mar 2020 11:46:24 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:46:14 GMT]]>Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal Rescue Pen for treatment of severe hypoglycemia

The Dasiglucagon HypoPal Rescue Pen New Drug Application represents a major milestone in Zealand Pharmas efforts to bring life changing therapies to people with diabetes

]]>https://dev.proinvestor.com/forum/post/10492616https://dev.proinvestor.com/forum/post/10492616Tue, 31 Mar 2020 11:46:14 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 11:46:05 GMT]]>Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal Rescue Pen for treatment of severe h

Press Release No. 04 / 2020

]]>https://dev.proinvestor.com/forum/post/10492611https://dev.proinvestor.com/forum/post/10492611Tue, 31 Mar 2020 11:46:05 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 10:57:27 GMT]]>... stay tuned ...

]]>https://dev.proinvestor.com/forum/post/10492608https://dev.proinvestor.com/forum/post/10492608Tue, 31 Mar 2020 10:57:27 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:30:52 GMT]]>The New Ordinary Shares have been issued today and are expected to be admitted to trading on Nasdaq Copenhagen on April 1, 2020 in Zealands permanent ISIN code DK0060257814.

The amendments to Zealands articles of association required by the capital increase have been registered today with the Danish Business Authority.

]]>https://dev.proinvestor.com/forum/post/10492602https://dev.proinvestor.com/forum/post/10492602Tue, 31 Mar 2020 07:30:52 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:29:55 GMT]]>The New Ordinary Shares rank pari passu with Zealands existing shares and carry the same dividend and other rights. Each New Ordinary Share carries one vote at Zealands general meetings. Zealand only has one class of shares.

]]>https://dev.proinvestor.com/forum/post/10492605https://dev.proinvestor.com/forum/post/10492605Tue, 31 Mar 2020 07:29:55 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:29:49 GMT]]>The gross proceeds from the issuance of the New Ordinary Shares amounts to DKK 137,236,000.

Following the registration of the New Ordinary Shares with the Danish Business Authority, Zealands share capital amounts to DKK 36,887,952 divided into 36,887,952 shares with a nominal value of DKK 1 each.

]]>https://dev.proinvestor.com/forum/post/10492600https://dev.proinvestor.com/forum/post/10492600Tue, 31 Mar 2020 07:29:49 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:29:37 GMT]]>Copenhagen, March 31, 2020 In reference to Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) company announcement 09/2020 published March 26, 2020, regarding a private placement and directed issue of 741,816 new shares of the company (the New Ordinary Shares), Zealand Pharma A/S (Zealand) announces that it has today increased its share capital by DKK 741,816, divided into 741,816 New Ordinary Shares with a nominal value of DKK 1 each.

]]>https://dev.proinvestor.com/forum/post/10492598https://dev.proinvestor.com/forum/post/10492598Tue, 31 Mar 2020 07:29:37 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:28:49 GMT]]>Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase

Company announcement No. 11 / 2020

Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase

]]>https://dev.proinvestor.com/forum/post/10492601https://dev.proinvestor.com/forum/post/10492601Tue, 31 Mar 2020 07:28:49 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 07:12:18 GMT]]>Så er alle aktier solgt og der er købt massivt op i Bavarian.

]]>https://dev.proinvestor.com/forum/post/10492597https://dev.proinvestor.com/forum/post/10492597Tue, 31 Mar 2020 07:12:18 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 06:46:40 GMT]]>FV (fair value) er ikke meget over dagens kurs

]]>https://dev.proinvestor.com/forum/post/10492599https://dev.proinvestor.com/forum/post/10492599Tue, 31 Mar 2020 06:46:40 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 06:45:25 GMT]]>ZEAL - Bryan Garnier har udsendt en kommentar i dag http://prntscr.com/rpzunw

]]>https://dev.proinvestor.com/forum/post/10492604https://dev.proinvestor.com/forum/post/10492604Tue, 31 Mar 2020 06:45:25 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 06:42:42 GMT]]>BAVA - vedr. den meddelelse der sendtes ud i går om J&Js andel. Jeg tolker den som om at J&J er gået under 5% fordi de ikke har udnyttet deres tegningsretter. Altså et negativt signal. Desværre.

]]>https://dev.proinvestor.com/forum/post/10492594https://dev.proinvestor.com/forum/post/10492594Tue, 31 Mar 2020 06:42:42 GMT<![CDATA[Reply to Bavarian Nordic — Marts 2020 on Tue, 31 Mar 2020 06:10:57 GMT]]>Farmaceuten: ja det er sådan jeg tolker teksten.

]]>https://dev.proinvestor.com/forum/post/10492591https://dev.proinvestor.com/forum/post/10492591Tue, 31 Mar 2020 06:10:57 GMT